Edition:
United Kingdom

Reata Pharmaceuticals Inc (RETA.OQ)

RETA.OQ on NASDAQ Stock Exchange Global Market

33.23USD
23 May 2018
Change (% chg)

$1.21 (+3.78%)
Prev Close
$32.02
Open
$31.88
Day's High
$34.70
Day's Low
$31.28
Volume
76,639
Avg. Vol
65,599
52-wk High
$40.56
52-wk Low
$19.32

Latest Key Developments (Source: Significant Developments)

Reata Provides Update On Phase 2 Portion Of Cardinal Study Of Bardoxolone Methyl In Patients With Alport Syndrome
Wednesday, 11 Apr 2018 

April 11 (Reuters) - Reata Pharmaceuticals Inc ::REATA PROVIDES UPDATE ON THE PHASE 2 PORTION OF THE CARDINAL STUDY OF BARDOXOLONE METHYL IN PATIENTS WITH ALPORT SYNDROME.IN STUDY, BARDOXOLONE TREATMENT PRODUCED "SIGNIFICANT" INCREASE IN KIDNEY FUNCTION MAINTAINED THROUGH WEEK 36.BARDOXOLONE CONTINUES TO BE WELL-TOLERATED IN ALPORT SYNDROME PATIENTS.ADVERSE EVENTS HAVE BEEN GENERALLY MILD TO MODERATE IN SEVERITY, NO DRUG-RELATED SERIOUS ADVERSE EVENTS BEEN REPORTED IN TRIAL.  Full Article

Reata Pharmaceuticals- Entered Third Supplement To Exclusive License & Supply Agreement With Kyowa Hakko
Thursday, 7 Dec 2017 

Dec 7 (Reuters) - Kyowa Hakko Kirin Co Ltd <4151.T>::REATA PHARMACEUTICALS-ON DEC 7 CO ENTERED THIRD SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO, KYOWA HAKKO KIRIN CO LTD (KHK).REATA SAYS THIRD SUPPLEMENT ALLOWS CO TO BEGIN PORTION OF PHASE 3 CLINICAL STUDY OF RTA 402 IN FIELD OF ALPORT SYNDROME IN JAPAN - SEC FILING.REATA PHARMACEUTICALS - ON DEC 7 CO ENTERED FOURTH SUPPLEMENT TO EXCLUSIVE LICENSE & SUPPLY AGREEMENT, BY & BETWEEN CO & KHK.  Full Article

Reata Pharmaceuticals files for offering of up to $50.0 million of shares of Class A common stock‍​
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Reata Pharmaceuticals Inc ::Files for offering of up to $50.0 million of shares of Class A common stock‍​ - SEC filing.  Full Article

Reata Pharmaceuticals Q3 loss per share $0.50
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Reata Pharmaceuticals Inc :Reata Pharmaceuticals Inc announces third quarter 2017 financial and operating results.Q3 loss per share $0.50.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Reata Pharmaceuticals Inc - qtrly ‍total collaboration revenue $12.6 million versus $12.6 million.Reata Pharmaceuticals Inc - ‍as of September 30, 2017, company had $154.6 million in cash and cash equivalents​.  Full Article

Reata Pharmaceuticals enters first amendment to loan and security agreement​
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Reata Pharmaceuticals Inc :Reata Pharmaceuticals says ‍on November 3, co entered into a first amendment to loan and security agreement​ - SEC filing.Reata Pharmaceuticals Inc - ‍loan agreement was amended to increase amount of term B loan to $20 million prior to term B loan increase milestone​.Reata Pharmaceuticals Inc - ‍agreement was amended to increase amount of term B loan to $25 million following term B loan increase milestone​.  Full Article

Reata Pharmaceuticals says top-line data to be available in 2019 for omaveloxolone​
Monday, 23 Oct 2017 

Oct 23 (Reuters) - Reata Pharmaceuticals Inc -:Reata Pharmaceuticals Inc - ‍announces first patient enrolled in Part 2 of Moxie study of omaveloxolone for treatment of Friedreich's Ataxia​.Reata Pharmaceuticals Inc - Reata expects top-line data to be available in second half of 2019 for omaveloxolone​ ‍​.  Full Article

Reata Pharmaceuticals requests withdrawal of registration statement on Form S-1
Monday, 12 Dec 2016 

Reata Pharmaceuticals Inc : Reata Pharmaceuticals, Inc. Announces requested withdrawal of registration statement due to adverse market conditions . Reata Pharmaceuticals Inc - due to adverse market conditions, requested withdrawal of registration statement on Form S-1 that was filed on Dec 6, 2016 .Reata Pharmaceuticals Inc - registration statement not been declared effective by SEC, and no securities have been sold in connection with offering.  Full Article

Reata Pharma Announces Q2 2016 financial & operating results
Thursday, 11 Aug 2016 

Reata Pharmaceuticals Inc : Reata Pharmaceuticals, Inc. Announces second quarter 2016 financial and operating results . Q2 earnings per share view $-0.22 -- Thomson Reuters I/B/E/S .Q2 loss per share $0.05.  Full Article

CPMG Inc reports 18.1 pct stake in Reata Pharmaceuticals
Monday, 6 Jun 2016 

Reata Pharmaceuticals Inc :CPMG Inc reports 18.1 percent stake in Reata Pharmaceuticals Inc, as of May 25, 2016 - SEC filing.  Full Article

Abbvie reports 17.93 pct passive stake in Reata as of May 25 - SEC filing
Monday, 6 Jun 2016 

Reata Pharmaceuticals Inc :Abbvie Inc reports 17.93 pct passive stake in Reata Pharmaceuticals Inc as of May 25, 2016 - SEC filing.  Full Article

BRIEF-Reata Pharmaceuticals Posts Q1 Earnings Per Share $0.16

* REATA PHARMACEUTICALS, INC. ANNOUNCES FIRST QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS